Regulatory actions for July 24, 2026
AI Briefing
- Agilent receives FDA clearance for its AriaPlex 2.0 liquid handling platform.
- Astrazeneca's Evusheld gets EUA for COVID-19 treatment in patients with COVID-19 at high risk of progression to severe disease.
- Pfizer's PAXLOR receives FDA approval for treatment of pediatric patients with certain types of epilepsy.
Source Summary
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Agilent, Astrazeneca, Atsena, GSK, H. Lundbeck, Haisco, Ibex, Inhibikase, Momentis, Nuvectis, Pfizer, Revolution, Sentante, Traferox.
Advertisement